



Bank of America 38th Annual Investment Conference

September 15, 2008


Thomas C. Freyman
Executive VP, Finance and CFO
Abbott

Forward-Looking Statement

Comments will be made that are forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to Abbott's Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2007, and in Item 1A, "Risk Factors," to Abbott's Quarterly Report on Securities and Exchange Commission Form 10-Q for the quarter ended June 30, 2008, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

Diverse business portfolio

Abbott Sales by Operating Segment



2007 Full-Year Results

Worldwide Sales: \$26 billion ↑ **15%**

• Worldwide Pharmaceuticals ↑ 18%

• International Nutritionals ↑ 18%

• Worldwide Diagnostics ↑ 11%

• Worldwide Vascular ↑ 54%

Ongoing Earnings Per Share ↑ **12%**

Q2 2008 Results

Worldwide Sales: \$7.3 billion	↑	15%
• Worldwide Pharmaceuticals	↑	17%
• Worldwide Nutritionals	↑	13%
• Worldwide Diagnostics	↑	17%
• Worldwide Vascular	↑	16%
Ongoing Earnings Per Share	↑	22%

Outlook for reliable, double-digit growth

Creating Shareholder Value

Sustainable Core Abbott Franchises

Immunology



Lipid Management



Diagnostics



Vascular Care



Nutritionals



2008 New Product Momentum

Highly Productive Late-Stage Pipeline

Product	Launched in 2008
Humira Psoriasis	√
Humira JRA	√
Humira RA-Japan	√
Simcor	√
FreeStyle Navigator	√
FreeStyle Freedom Lite	√
Architect i1000	√
Xience V- U.S.	√
TriLipix	4Q08
Vicodin CR	4Q08

Future Growth Drivers

Broad-based Pipeline Highlights

Pharmaceuticals


- Neuroscience and pain management
- Oncology
- Immunology
- Respiratory disease
- Infectious disease

Medical Products

- Bioabsorbable drug-eluting stent
- Nutritionals packaging and products
- Diagnostics systems and tests




Genentech



Abbott

Geographically Diverse Business Portfolio


2007 Sales: \$26 billion



Advancing Abbott

Operational and Financial Flexibility

- Returning cash to shareholders
- Expect record operating cash flow in 2008
- Improving margins and returns



Pharmaceuticals

Growth drivers: Humira

- Biologic therapy
- Six indications in total
- \$20B WW biologics market
- Raised 2008 WW Humira sales guidance to >\$4.3B

HUMIRA – U.S. Approvals

6

Juvenile Idiopathic Arthritis
February 2008

5

Psoriasis
January 2008

4

Crohn's Disease
February 2007

3

Ankylosing Spondylitis
July 2006

2

Psoriatic Arthritis (PsA)
October 2005


1

Rheumatoid Arthritis
December 2002

Pharmaceuticals

Growth drivers: Lipid Management

Of the 30MM U.S. adults currently being treated for a lipid disorder:



Nutritional Products

Growth Drivers

- Key attributes of Nutritionals
 - Strong operating margins
 - High return on invested capital
 - Consistent cash flow
- U.S. Nutritional Products
 - Launching new and improved products
- Abbott Nutrition International
 - Rapid growth in emerging markets
 - Strong double-digit growth expected longer term



Medical Products

Growth Drivers: Diabetes, Molecular, Diagnostics

- Abbott Diabetes Care
- Abbott Molecular
 - Strong double-digit sales growth
- Diagnostics
 - Emerging market opportunity
 - Focus on profitability



Medical Products

Growth Drivers: Abbott Vascular

- Leadership in vascular care
- U.S. Xience launch exceeding expectations
- U.S. market improving
- Xience platform market leader in Europe



Advancing Abbott

Unique Well-Balanced Portfolio

- Diverse mix of growth businesses
- Competing in high-growth, innovation driven markets
- Well positioned to maintain market leadership
- Outlook for strong, reliable, double-digit growth





Bank of America 38th Annual Investment Conference

September 15, 2008

Thomas C. Freyman
Executive VP, Finance and CFO
Abbott